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OBJECTIVE—There is a complex relationship between IGF-I,
IGF binding proteins, growth hormone, and insulin. The IGF-I
kinase receptor activation assay (KIRA) is a novel method for
measuring IGF-I bioactivity in human serum. We speculated that
determination of IGF-I bioactivity might broaden our understand-
ing of the IGF-I system in subjects with the metabolic syndrome.
The purpose of our study was to investigate whether IGF-I
bioactivity was related to insulin sensitivity and the metabolic
syndrome.
RESEARCH DESIGN AND METHODS—We conducted a
cross-sectional study embedded in a random sample (1,036
elderly subjects) of a prospective population-based cohort study.
IGF-I bioactivity was determined by the IGF-I KIRA. Categories
of glucose (in)tolerance were deﬁned by the 2003 American
Diabetes Association criteria. Insulin sensitivity was assessed by
homeostasis model assessment. The Adult Treatment Panel III
deﬁnition of the metabolic syndrome was used.
RESULTS—In subjects with normal fasting glucose and im-
paired fasting glucose, IGF-I bioactivity progressively increased
with increasing insulin resistance, peaked at fasting glucose
levels just below 7.0 mmol/l, and dropped at higher glucose
levels. Mean IGF-I bioactivity peaked when three criteria of the
metabolic syndrome were present and then declined signiﬁcantly
when ﬁve criteria of the metabolic syndrome were present.
CONCLUSIONS—We observed that IGF-I bioactivity was re-
lated to insulin sensitivity, insulin levels, and the metabolic
syndrome. Our study suggests that there exists an inverse
U-shaped relationship between IGF-I bioactivity and number of
components of the metabolic syndrome. This observation con-
trasts with previous results reporting an inverse relationship
between total IGF-I and components of the metabolic syndrome.
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A
complex relationship exists between IGF-I,
IGF binding proteins (IGFBPs), growth hor-
mone (GH), and insulin. GH exerts potent
effects on intermediary metabolism by antag-
onizing insulin action (1). IGF-I directly inhibits insulin
secretion and increases insulin sensitivity (2). Insulin
appears to be necessary for normal liver GH responsive-
ness, probably by maintaining liver GH receptor levels (3).
However, chronic hyperinsulinemia reduces GH receptor
expression and signaling in the liver (4,5). The majority of
circulating IGF-I is bound to six IGFBPs that are important
in determining IGF-I availability and activity (6).
Recently, the IGF-I–speciﬁc kinase receptor activation
assay (KIRA) was developed to determine circulating IGF
bioactivity (7,8). This bioassay determines IGF-I bioactiv-
ity by measuring intracellular receptor auto-phosphoryla-
tion upon IGF-I binding. Unlike IGF-I immunoassays, the
IGF-I KIRA takes into account the modifying effects of
IGFBPs on the interaction between IGF-I and the IGF-I
receptor (IGF-IR) (9). The aim of the present study was to
investigate whether IGF-I bioactivity was related to insulin
sensitivity, insulin levels, and the metabolic syndrome in
an elderly population-based cohort.
RESEARCH DESIGN AND METHODS
The Rotterdam Study is a prospective population-based cohort study investi-
gating incidence and risk factors of cardiovascular diseases in elderly people
(10). The ethics committee of Erasmus MC approved the study, and written
informed consent was obtained from all participants.
Fasting blood samples were obtained after an overnight fast in participants
without known diabetes. In subjects with diabetes, blood was drawn prior to
the intake of antidiabetic agents. Fasting plasma glucose (FPG) was deter-
mined using the hexokinase method (Boehringer Mannheim, Mannheim,
Germany). American Diabetes Association 2003 criteria were used to classify
glucose tolerance as normal fasting glucose (NFG), FPG 5.6 mmol/l;
impaired fasting glucose (IFG), FPG 5.6–6.9 mmol/l; and diabetes, FPG 7
mmol/l (11). Serum total and HDL cholesterol were determined using an
automatic enzymatic procedure (Boehringer Mannheim). Serum triglycerides
were analyzed by Triglyceride GPO-PAP (Roche Diagnostics, Mannheim,
Germany). Insulin was measured with an electrochemiluminescence immu-
noassay (Roche Diagnostics; intra- and interassay coefﬁcient of variation [CV]
3.7%, with cross-reactivity of 20% with des-31, 32-proinsulin, per the manu-
facturer). Sitting blood pressure (mean of two readings) was measured using
a random-zero sphygmomanometer.
IGF-I bioactivity was measured using an IGF-I kinase receptor activation
assay (KIRA) (intra- and interassay CVs of 5.2 and 12.2%, respectively;
cross-reactivity of 15% for IGF-II) (8,12). IGF-I bioactivity was measured in
1,050 blood samples randomly selected from 3,792 individuals who partici-
pated in the survey. Fourteen subjects were excluded from analysis because
their measurements of IGF-I bioactivity repeatedly did not pass deﬁned
acceptance criteria (intra-assay CV 10%). In 904 of 1,036 subjects (87%) all
parameters of the metabolic syndrome were available; 132 subjects had one or
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concerning the metabolic syndrome.
The updated homeostasis model assessment (HOMA-2) was used to assess
insulin sensitivity (%S), insulin resistance (HOMA-IR), which is the reciprocal
of %S, and -cell function from pairs of fasting glucose and insulin levels (13).
The Adult Treatment Panel III (ATP-III) criteria were used to diagnose the
metabolic syndrome (14).
Statistical analysis. Pearson’s correlation coefﬁcients were calculated to
assess (age-adjusted) associations between variables. Univariate ANCOVA
were used to compare variables stratiﬁed by deciles of HOMA-IR, adjusted for
age, sex, BMI, and antidiabetic therapy when appropriate. In 904 of 1,036
subjects (87%) all parameters of the metabolic syndrome were available; 132
subjects had one or more missing values and were therefore excluded from
statistical analyses concerning the metabolic syndrome.
A two-sided probability of P  0.05 was considered statistically signiﬁcant.
All analyses were performed with SPSS for Windows version 15 (SPSS,
Chicago, IL).
RESULTS
The mean age of the study population of 1,036 subjects
(451 male) was 72.4 years (95% CI 62.8–86.3), and the
mean BMI was 26.9 kg/m
2 (21.5–33.9). Based on 2003
American Diabetes Association criteria, 697 subjects
(69.7%) had NFG, 165 subjects (16.3%) had IFG, and 153
subjects (15.1%) had diabetes. A total of 62 subjects (6%)
had known diabetes, of which 19 (1.8%) were treated with
diet only and 39 (3.8%) were treated with oral antidiabetic
agents.
Mean  SE IGF-I bioactivity was signiﬁcantly lower in
men (168.9  2.5 pmol/l) than in women (187.0  3.1
pmol/l, P  0.001 after adjustment for age and BMI). There
was no association between IGF-I bioactivity and fasting
insulin (r  0.049, P  0.206). However, when analysis was
conﬁned to subjects with NFG, IGF-I bioactivity was
signiﬁcantly and positively related to fasting insulin (r 
0.096, age-adjusted, P  0.036). Mean  SE IGF-I bioac-
tivity did not differ between diabetic subjects with (169 
8.7 pmol/l) and without (179  1.8 pmol/l, P  0.47) oral
antidiabetic agents.
After adjustment for age, overall IGF-I bioactivity was
inversely related to insulin sensitivity (r  0.113, P 
0.003), while the relationship between IGF-I bioactivity
and -cell function was borderline signiﬁcant (r  0.065,
P  0.088). When subjects were stratiﬁed to deciles of
insulin resistance (HOMA-IR), mean FPG and insulin lev-
els progressively increased with increasing insulin resis-
tance. For mean IGF-I bioactivity there was a progressive
increase with increasing insulin resistance up to and
including the 9th decile (P for trend  0.003) (Fig. 1).
However, when mean FPG levels met diagnostic criteria
for diabetes in the 10th decile, IGF-I bioactivity dropped
signiﬁcantly compared with the 9th decile (P  0.005) (Fig.
1). When analyses were repeated after excluding diabetic
subjects on medical therapy, the outcome was unaffect-
ed—IGF-I bioactivity increased signiﬁcantly up to and
including the 9th decile of HOMA-IR (P for trend  0.006)
and decreased signiﬁcantly in the 10th decile (P  0.010
for the 9th vs. 10th decile).
Mean HOMA-IR increased signiﬁcantly per increasing
number of components of the metabolic syndrome (P for
trend  0.001, adjusted for age and sex). As expected,
mean FPG levels also increased progressively with an
increasing number of components of the metabolic syn-
drome. Mean fasting insulin levels were signiﬁcantly
higher in subjects with ﬁve components of the metabolic
syndrome than in subjects with four or fewer components
of the metabolic syndrome. Up to a point, IGF-I bioactivity
was also directly related to number of components of the
metabolic syndrome, peaking when three components
were present and the diagnosis of the metabolic syndrome
could be made. However, in subjects with more than three
components of the metabolic syndrome, IGF-I bioactivity
decreased signiﬁcantly (mean IGF-I bioactivity in subjects
with three vs. ﬁve components P  0.04, adjusted for age
and sex) (Fig. 2).
DISCUSSION
The main ﬁnding of our study is that circulating IGF-I
bioactivity progressively increases with increasing sever-
ity of insulin resistance and hyperinsulinemia. At FPG
levels just below 7.0 mmol/l, mean IGF-I bioactivity
reached a plateau. However, in subjects with diabetes,
mean IGF-I bioactivity was signiﬁcantly lower than in
subjects with NFG and IFG.
Strong evidence exists that insulin is essential for GH
stimulation of hepatic IGF-I production (3). Insulin deﬁ-
ciency results in a decreased liver GH receptor expression,
which can be reversed by insulin administration (3,15). On
the other hand, patients with type 2 diabetes often exhibit
reduced circulating total IGF-I levels (16). One explana-
tion is that chronic hyperinsulinemia induces GH receptor
resistance (4). Under experimental conditions, hyperinsu-
linemia reduces not only GH receptor expression but also
GH signaling both at receptor and postreceptor levels
(4,5). Although the direction of cause and effect may be
difﬁcult to assess in a cross-sectional study, this opens the
possibility that the observed decline in IGF-I bioactivity in
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FIG. 1. Mean  SEM IGF-I bioactivity stratiﬁed per decile of HOMA-IR.
Statistical differences between deciles were calculated after adjust-
ment for age, BMI, and sex. P for trend < 0.001, **P  0.005.
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FIG. 2. Relationship between the number of components of the meta-
bolic syndrome and mean  SEM IGF-I bioactivity. *P  0.03, **P 
0.04.
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hepatic GH resistance.
Several epidemiological studies have linked low circu-
lating total IGF-I, particularly when coupled with low
levels of the potentially inhibitory IGFBP-1, to an in-
creased risk of the metabolic syndrome (17–21). An in-
creased ratio of total IGF-I to IGFBP-1 has been proposed
as a surrogate marker of increased IGF-I bioactivity (22).
This is probably a compensatory mechanism to maintain
normal glucose tolerance, since raised IGF-I bioactivity
improves insulin sensitivity (23). High IGF-I bioactivity
may suppresses GH secretion as part of a negative feed-
back system, thereby inducing lower total IGF-I levels
(22). This may explain why low total IGF-I levels have
been previously reported to be associated with the meta-
bolic syndrome (20).
Our study demonstrates that IGF-I bioactivity declines
during progression of the metabolic syndrome. Because
individuals with the metabolic syndrome are chronically
exposed to high circulating insulin levels, the increase in
IGF-I bioactivity in subjects with one to three components
of the metabolic syndrome may be due to an insulin-
mediated suppression of IGFBP-1 levels (24). However, in
subjects with more than three components of the meta-
bolic syndrome, IGF-I bioactivity signiﬁcantly declined.
The lower IGF-I bioactivity in these latter individuals may
be a direct consequence of the development of hepatic
insulin resistance (manifested by a relative increase of
IGFBP-1) and hyperinsulinemia-induced GH resistance.
A limitation of our study is that no comparisons were
made between circulating IGF-I bioactivity and total IGF-I
measurements. However, we previously found a weak
correlation between circulating total IGF-I levels and IGF-I
bioactivity, suggesting that the IGF-I KIRA produces infor-
mation about the IGF-I system that essentially differs from
that obtained by IGF-I immunoassays (12).
Another shortcoming of this study is that we did not
perform oral glucose tolerance tests. Therefore, it is not
clear how many subjects had IGT or even diabetes that
was not assessed by fasting glucose alone. In addition,
HOMA-IR does not always reﬂect insulin sensitivity accu-
rately in subjects with differing -cell function.
In conclusion, our study suggests that an individual’s
insulin sensitivity and circulating insulin levels directly
modulate IGF-I bioactivity. When insulin resistance be-
comes apparent, but glucose levels are still within the
normal range, there is an initial rise in circulating IGF-I
bioactivity. However, when glucose tolerance rises to the
point where IFG occurs, IGF-I bioactivity reaches a plateau.
Finally, when blood glucose levels have risen into overt type
2 diabetes, circulating IGF-I bioactivity progressively de-
clines. IGF-I bioactivity seems also to be related to the
metabolic syndrome. Our study suggests that there exists an
inverse U-shaped relationship between IGF-I bioactivity and
number of components of the metabolic syndrome.
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